Health-care companies rose as vaccine hopes buoyed pharmaceutical companies.
Shares of Pfizer and partner BioNTech rallied after a Food and Drug Administration review indicated that the Covid-19 vaccine candidate they developed likely has a "favorable safety profile." Peer-reviewed data from late-stage human trials of a Covid-19 vaccine developed by the University of Oxford and AstraZeneca reaffirmed the shot's strong safety results and provided some additional evidence that halving the first of two doses of the shot boosts its effectiveness, as reported earlier.
Shareholders of bankrupt Mallinckrodt urged a judge to appoint an official equity committee in the drugmaker's chapter 11 case, a request that could give them a seat at the negotiating table during the company's restructuring.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
12-08-20 1736ET
